American Association for Cancer Research
15357163mct160739-sup-174128_3_figure_4160411_ft2fpk.png (2.72 MB)

Supplementary Figure 4 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers

Download (2.72 MB)
posted on 2023-04-03, 16:01 authored by Luxi Chen, Yi Yuan, Shreya Kar, Madhu M. Kanchi, Suruchi Arora, Ji E. Kim, Pei F. Koh, Einas Yousef, Ramar P. Samy, Muthu K. Shanmugam, Tuan Z. Tan, Sung W. Shin, Frank Arfuso, Han M. Shen, Henry Yang, Boon C. Goh, Joo I. Park, Louis Gaboury, Peter E. Lobie, Gautam Sethi, Lina H.K. Lim, Alan P. Kumar

Supplementary Figure 4: PPARγ ligand-induced changes in expression of RIP1 and NEMO and therefore NFκB activity are receptor dependent.



Metastatic breast cancer is still incurable so far; new specifically targeted and more effective therapies for triple-negative breast cancer (TNBC) are required in the clinic. In this study, our clinical data have established that basal and claudin-low subtypes of breast cancer (TNBC types) express significantly higher levels of Annexin A1 (ANXA1) with poor survival outcomes. Using human cancer cell lines that model the TNBC subtype, we observed a strong positive correlation between expression of ANXA1 and PPARγ. A similar correlation between these two markers was also established in our clinical breast cancer patients' specimens. To establish a link between these two markers in TNBC, we show de novo expression of ANXA1 is induced by activation of PPARγ both in vitro and in vivo and it has a predictive value in determining chemosensitivity to PPARγ ligands. Mechanistically, we show for the first time PPARγ-induced ANXA1 protein directly interacts with receptor interacting protein-1 (RIP1), promoting its deubiquitination and thereby activating the caspase-8–dependent death pathway. We further identified this underlying mechanism also involved a PPARγ-induced ANXA1-dependent autoubiquitination of cIAP1, the direct E3 ligase of RIP1, shifting cIAP1 toward proteosomal degradation. Collectively, our study provides first insight for the suitability of using drug-induced expression of ANXA1 as a new player in RIP1-induced death machinery in TNBCs, presenting itself both as an inclusion criterion for patient selection and surrogate marker for drug response in future PPARγ chemotherapy trials. Mol Cancer Ther; 16(11); 2528–42. ©2017 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager